Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • InterCure (INCR.U) has opened the first “LEMONNADE” branch in Israel as part of the “Givol” pharmacy chain
  • The pharmacy received its cannabis dispensing license from the Israeli Medical Cannabis Agency (IMCA) on April 27th
  • The branch will operate and provide services to medical cannabis patients in Jerusalem
  • The Givol pharmacy chain is the first and the leading chain of pharmacies focused on medical cannabis in Israel
  • InterCure (dba Canndoc) is the fastest-growing and most profitable Israeli cannabis company
  • InterCure (INCR.U) is down 1.81 per cent, trading at C$7.07 per share at 1:15 pm ET

InterCure (INCR.U) has opened the first “LEMONNADE” branch in Israel as part of the “Givol” pharmacy chain.

The pharmacy has officially begun operating after received its cannabis dispensing license from the Israeli Medical Cannabis Agency (IMCA) on April 27, 2021.

This is the first branch under the “LEMONNADE” brand outside of North America to begin operations. The branch will operate and provide services to the community of medical cannabis patients in Jerusalem, which has one of the highest numbers of licensed cannabis patients in Israel.

The Givol pharmacy chain is the first and the leading chain of pharmacies focused on medical cannabis in Israel. The chain currently includes ten pharmacies across Israel. In addition, the chain operates a nationwide ordering and delivery licensed service that covers the entire medical cannabis patients’ community in Israel.

Givol chain is in growth momentum and management is working to expand the chain by among other things, the acquisition of additional pharmacies and expanding to new territories including Europe.

InterCure (dba Canndoc) is the fastest-growing and most profitable Israeli cannabis company.

Canndoc, a wholly-owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products.

InterCure (INCR.U) is down 1.81 per cent, trading at C$7.07 per share at 1:15 pm ET.

More From The Market Herald
MediPharm Labs - Asia Pacific CEO, Warren Everitt

" MediPharm Labs (TSX:LABS) announces cannabis oil delivery to Vayamed

MediPharm Labs (LABS) has completed another GMP cannabis extract delivery to Germany.
Levitee Labs - CEO, Pouya Farmand.

" Levitee Labs (CSE:LVT) partners with Adracare for addiction and mental health support

Levitee Labs (LVT) has signed an agreement with Adracare to develop a platform for mental health services.
CBD Global Sciences - Brad Wyatt, President and CEO

" CBD Global Sciences(CSE:CBDN) purchases Resinosa LLC

CBD Global Sciences Inc. (CBDN) has acquired 100 per cent of the Colorado-based company, Resinosa LLC.
HEXO Corp - Departing CEO, Sebastien St. Louis.

" HEXO’s (TSX:HEXO) St-Louis out as CEO

HEXO (HEXO) has announced executive changes as it completes a strategic reorganization.